Business Context and Reporting Period
Company: TECHNE Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2005
Overview: TECHNE Corporation is a holding company with two primary operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, MN, and R&D Systems Europe Ltd. in Abingdon, England. The company operates through three segments: the Biotechnology Division (cytokines, antibodies, assay kits), the Hematology Division (blood analysis controls and calibrators), and R&D Europe (distribution of biotechnology products in Europe). The company is a leading supplier of cytokine-related products to the research marketplace and a major supplier of hematology controls.
Key Financial Metrics
| Metric | Fiscal 2005 | Fiscal 2004 | Fiscal 2003 |
|---|---|---|---|
| Net Sales | $178.7 million | $161.3 million | $145.0 million |
| Gross Margin | 79.4% | 78.4% | 75.6% |
| Operating Income | $97.8 million | $82.3 million | $67.7 million |
| Net Earnings | $66.1 million | $52.9 million | $45.4 million |
| Diluted EPS | $1.62 | $1.27 | $1.08 |
| Cash from Operations | $74.4 million | $65.6 million | $55.2 million |
| Capital Expenditures | $11.4 million | $3.7 million | $15.2 million |
| Long-Term Debt | $13.4 million | $14.6 million | $15.9 million |
| Cash & Investments | $97.1 million | $93.7 million | $118.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10.8% to $178.7 million, driven primarily by an 11.8% increase in the Biotechnology Division ($111.2 million) and an 8.9% increase in R&D Europe sales (in local currency). The Hematology Division saw a slight decline due to reduced sales to one OEM customer.
- Profitability: Net earnings rose 24.9% to $66.1 million. This was aided by a lower effective tax rate (33.8% vs. 35.9%), improved gross margins, and the elimination of equity investment losses from ChemoCentryx (CCX) and Discovery Genomics (DGI) that impacted prior periods.
- Investment Accounting Changes: The company switched from the equity method to the cost method for its investment in CCX in May 2004, removing CCX's operating losses from consolidated R&D expenses. Additionally, a $1.5 million impairment loss on the DGI investment was recorded in fiscal 2004, which did not recur in 2005.
- Stock Repurchase: In March 2005, the company initiated an Accelerated Stock Buyback (ASB) transaction for approximately 2.9 million shares with an initial value of $100 million, significantly reducing outstanding shares.
Outlook, Risks, and Unusual Items
- Acquisitions: Subsequent to the fiscal year-end (July 2005), the company acquired Fortron Bio Science, Inc. and BiosPacific, Inc. for $20 million in cash to expand its diagnostic market presence.
- Accounting Changes: The company will adopt SFAS No. 123R (Share-Based Payment) in fiscal 2006, which is expected to increase compensation expense by approximately $1.2 million ($0.03 per diluted share).
- Market Risks:
- Currency: Approximately 25% of sales are in foreign currencies (primarily British Pound). A 10% fluctuation in exchange rates could impact operating income by approximately $1.4 million.
- Customer Concentration: No single customer accounted for more than 10% of revenue. However, OEM contracts represent a small but material portion of Hematology sales.
- Regulatory: Hematology controls and certain diagnostic kits are subject to FDA regulation. Delays in approvals for new diagnostic products could impact future growth.
- Investment Risks: The company holds equity interests in ChemoCentryx ($5.1 million) and Hemerus Medical ($2.6 million). These investments are subject to impairment risks if the investees fail to secure funding or regulatory clearance.
Key Facts for Investor Verification
- ASB Settlement: Verify the final settlement terms of the $100 million Accelerated Stock Buyback, which is subject to a market price adjustment through December 2005.
- Integration of Acquisitions: Monitor the financial impact and integration progress of the Fortron and BiosPacific acquisitions completed in July 2005.
- Stock-Based Compensation: Track the actual impact of SFAS 123R adoption in fiscal 2006 on net earnings and EPS.
- Investment Valuation: Review the status of equity investments in ChemoCentryx and Hemerus Medical for potential future impairment charges.
- Foreign Exchange Exposure: Assess the impact of GBP/USD exchange rate fluctuations on the R&D Europe segment's contribution to consolidated earnings.